These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 34966256)

  • 1. Hoehn and Yahr Stage and Striatal Dat-SPECT Uptake Are Predictors of Parkinson's Disease Motor Progression.
    Jackson H; Anzures-Cabrera J; Taylor KI; Pagano G; ;
    Front Neurosci; 2021; 15():765765. PubMed ID: 34966256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.
    Pagano G; Boess FG; Taylor KI; Ricci B; Mollenhauer B; Poewe W; Boulay A; Anzures-Cabrera J; Vogt A; Marchesi M; Post A; Nikolcheva T; Kinney GG; Zago WM; Ness DK; Svoboda H; Britschgi M; Ostrowitzki S; Simuni T; Marek K; Koller M; Sevigny J; Doody R; Fontoura P; Umbricht D; Bonni A; ;
    Front Neurol; 2021; 12():705407. PubMed ID: 34659081
    [No Abstract]   [Full Text] [Related]  

  • 3. Associations of striatal dopamine transporter binding with motor and non-motor symptoms in early Parkinson's disease.
    Yang Z; Xie Y; Dou K; Yang L; Xie A
    Clin Transl Sci; 2023 Jun; 16(6):1021-1038. PubMed ID: 36915231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
    Simuni T; Uribe L; Cho HR; Caspell-Garcia C; Coffey CS; Siderowf A; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Tosun D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten SJ; Bressman S; Marek K;
    Lancet Neurol; 2020 Jan; 19(1):71-80. PubMed ID: 31678032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does the MDS-UPDRS provide the precision to assess progression in early Parkinson's disease? Learnings from the Parkinson's progression marker initiative cohort.
    Regnault A; Boroojerdi B; Meunier J; Bani M; Morel T; Cano S
    J Neurol; 2019 Aug; 266(8):1927-1936. PubMed ID: 31073716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantified Striatal Dopaminergic Denervation as Predictor for Motor Outcomes in Parkinson's Disease.
    Trinh I; Muralidhar A; Yang J; Phielipp N
    Mov Disord Clin Pract; 2023 Jun; 10(6):896-902. PubMed ID: 37332639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation.
    Latourelle JC; Beste MT; Hadzi TC; Miller RE; Oppenheim JN; Valko MP; Wuest DM; Church BW; Khalil IG; Hayete B; Venuto CS
    Lancet Neurol; 2017 Nov; 16(11):908-916. PubMed ID: 28958801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Constipation is not associated with dopamine transporter pathology in early drug-naïve patients with Parkinson's disease.
    Pagano G; Yousaf T; Wilson H; Niccolini F; Polychronis S; Chaudhuri KR; Politis M
    Eur J Neurol; 2018 Feb; 25(2):307-312. PubMed ID: 29078029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting Progression in Parkinson's Disease Using Baseline and 1-Year Change Measures.
    Chahine LM; Siderowf A; Barnes J; Seedorff N; Caspell-Garcia C; Simuni T; Coffey CS; Galasko D; Mollenhauer B; Arnedo V; Daegele N; Frasier M; Tanner C; Kieburtz K; Marek K;
    J Parkinsons Dis; 2019; 9(4):665-679. PubMed ID: 31450510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antihypertensive drugs may not delay the symptom progression of Parkinson's disease: A 2-year follow-up study.
    Dong Z; Zuo R; Zhong X; Zhang C; Zou X; Tian Y; Zuo H; Du X; Yu Q; Cheng O
    Heliyon; 2023 Aug; 9(8):e18538. PubMed ID: 37560660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Machine learning for predicting cognitive decline within five years in Parkinson's disease: Comparing cognitive assessment scales with DAT SPECT and clinical biomarkers.
    Gorji A; Fathi Jouzdani A
    PLoS One; 2024; 19(7):e0304355. PubMed ID: 39018311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of texture analysis to DAT SPECT imaging: Relationship to clinical assessments.
    Rahmim A; Salimpour Y; Jain S; Blinder SA; Klyuzhin IS; Smith GS; Mari Z; Sossi V
    Neuroimage Clin; 2016; 12():e1-e9. PubMed ID: 27995072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved motor outcome prediction in Parkinson's disease applying deep learning to DaTscan SPECT images.
    Adams MP; Rahmim A; Tang J
    Comput Biol Med; 2021 May; 132():104312. PubMed ID: 33892414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it?
    Pirker W
    Mov Disord; 2003 Oct; 18 Suppl 7():S43-51. PubMed ID: 14531046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucocerebrosidase Mutations and Motor Reserve in Parkinson's Disease.
    Chung SJ; Lee PH; Sohn YH; Kim YJ
    J Parkinsons Dis; 2021; 11(4):1715-1724. PubMed ID: 34459414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling of Parkinson's Disease Progression and Implications for Detection of Disease Modification in Treatment Trials.
    Ribba B; Simuni T; Marek K; Siderowf A; Diack C; Pierrillas PB; Monnet A; Ricci B; Nikolcheva T; Pagano G
    J Parkinsons Dis; 2024; 14(6):1225-1235. PubMed ID: 39058452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bidirectional Correlations Between Dopaminergic Function and Motivation in Parkinson's Disease.
    Hinkle JT; Mills KA; Perepezko K; Pontone GM
    J Geriatr Psychiatry Neurol; 2022 May; 35(3):353-362. PubMed ID: 33622073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma sphingolipids, dopaminergic degeneration and clinical progression in idiopathic Parkinson's disease.
    Yang R; He C; Zhang P; Li Y; Rong S; Chen X; Qi Q; Gao Z; Chi J; Wang L; Cai M; Zhang Y
    Parkinsonism Relat Disord; 2024 Sep; 126():107071. PubMed ID: 39053098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Motor subtypes and clinical characteristics in sporadic and genetic Parkinson's disease groups: analysis of the PPMI cohort.
    Jeong EH; Lee JY; Han SK; Song YS
    Front Neurol; 2023; 14():1276251. PubMed ID: 37954645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [123I]beta-CIT SPECT demonstrates decreased brain dopamine and serotonin transporter levels in untreated parkinsonian patients.
    Haapaniemi TH; Ahonen A; Torniainen P; Sotaniemi KA; Myllylä VV
    Mov Disord; 2001 Jan; 16(1):124-30. PubMed ID: 11215571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.